Importance Score: 75 / 100 🔴
Pharmaceutical giant AstraZeneca has announced amplified investment in the United States, signaling that Europe is slipping behind in the global drugs industry. The company’s CEO, Pascal Soriot, emphasizes the significant US role in backing pharmaceutical innovation.
The Shift Toward the United States Medicine Sector
Soriot reiterated intentions to enlarge the business in America, where it currently garners 40 percent of total sales. The executive also revealed plans to relocate manufacturing operations across the Atlantic to evade potential tariffs on pharmaceutical imports proposed by the Trump administration.
“Looking at the substantial investment flooding into the US, it clearly signals that Europe must augment its contribution to pharmaceutical innovation,” Soriot stated. “Otherwise, both manufacturing and research and development jobs will gradually migrate to the United States.”
President Trump has repeatedly threatened to impose tariffs on drug imports, which could heighten the cost of life-saving treatments for Americans and incentivise companies like AstraZeneca to increase domestic production.
The CEO’s Stance on Tariffs
- Soriot alerts drugs industry to these tariffs
- AstraZeneca believes better tax incentives would attract manufacturing and research investments
- Plans to move production will mitigate tariff impacts post-2025
AstraZeneca Forecast and Global Expansion
AstraZeneca, the leading UK-based company valued at £160 billion, reported a 10 percent revenue increase for the first quarter of 2025. This growth was driven by robust cancer drug sales, with the oncology division experiencing a 13 percent business surge.
Separately, AstraZeneca faces a potential fine in China over alleged unpaid import taxes. Authorities in Shenzhen claim the unpaid taxes total £1.2 million, with potential fines ranging from one to five times that amount if the company is found liable—to £6 million.
Despite the regulatory challenges, Soriot affirmed, “We remain deeply committed to China, as it constitutes a crucial market for us.”
Investing Accounts Comparisons
AJ Bell
Simple investing with ready-made portfolios
Hargreaves Lansdown
Complimentary fund trading and investment ideas
Interactive Investor
Flat-fee investing from £4.99 per month
InvestEngine
Account and trading fee-free ETF investing
Trading 212
Complimentary share dealing, no account fee
Affiliate links: If you take out a product this site may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.